Divalproex Sodium
Product Images NDC 17856-0798

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 17856-0798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (17856 0798 01 Label)

Packaging label for Divalproex Sodium 500 mg delayed-release tablet by Atlantic Biologicals Corp. The label indicates the product is unit dose with one tablet per pouch, 100 tablets per case. Manufacturer is Sun Pharmaceuticals Industries Ltd. Additional instructions include storage temperature and safety warnings to keep out of reach of children.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar chart titled Figure 1 comparing percentages for two studies (Study 1 using YMRS and Study 2 using MRS). It shows higher percentage values for Divalproex Sodium (DVPX) compared to placebo (PBO) in both studies: 60% versus 26% for Study 1 and 58% versus 29% for Study 2.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative response curve graph comparing percent reduction in CPS rate between Divalproex Sodium (DVPX) and placebo. The vertical axis shows the percentage reduction from -100% to 100%, indicating improvement or worsening, and the horizontal axis shows the percentage of patients from 0 to 100%. Two lines represent DVPX and placebo response distributions respectively.*

FDA Label Image

Ispl-divalproex-figure-3 (Spl Divalproex Figure 3)

A graph titled Figure 3 depicting the percent reduction in CPS rate versus percent of patients for Divalproex Sodium. It compares high dose (solid line) and low dose (dashed line) responses, showing improvement and worsening trends along the vertical axis labeled with improvement at the top and worsening at the bottom.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar graph titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and Divalproex Sodium (DVPX) across two studies. The y-axis measures migraine rates from 0 to 6, while the x-axis separates Study 1 and Study 2. Bars show lower migraine rates for Divalproex Sodium versus placebo in both studies.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of divalproex sodium, showing its molecular arrangement with sodium ion and organic groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.